drugset / Trial / NCT04805060

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors

NCT04805060

NaSequentialOpen-labelTreatment

Summary

This study is a phase I study to evaluate the safety and tolerability of TQB2858 injection in patients with advanced malignancy.

Timeline

Start
2021-04-23
Primary completion
2021-12-12
Completion
2025-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB2858 Protein / enzyme biologic Intravenous

Indications